Table 1.

Characteristics of the studies included in the case-control analysis.

First author	Year	Country	Cases	Number of cases	Number of controls	Study design	Serology assay
Mundkur [68]	2012	India	CAD	433	433	Prospective	ELISA
Haider [67]	2011	India	CAD	63	40	Cross-sectional	ELISA
Jha [65]	2009	India	CAD	192	192	Case-control	ELISA
Jafarzadeh [64]	2008	Iran	IHD	62	31	Case-control	ELISA
Videm [63]	2007	Norway	CAD	131	103	Case-control	ELISA
Corrado [59]	2006	Italy	A	456	212	Prospective	ELISA
Kaperonis [61]	2006	Greece	PAD	51	30	Cross-sectional	ELISA
Romano Carratelli [62]	2006	Italy	CAD	60	20	Case-control	MIF
Adiloglu [57]	2005	Turkey	A	88	91	Case-control	ELISA
Lanza [55]	2004	Italy	SA, cardiac SX	104	60	Case-control	MIF
Linares-Palomino [56]	2004	Spain	PAD	64	50	Case-control	MIF
Biasucci [51]	2003	Italy	UA, MI	259	100	Prospective	MIF
Georges [53]	2003	Germany	SA, UA	991	333	Case-control	MIF
Bloemenkamp [49]	2002	Netherlands	PAD	228	643	Case-control	ELISA
Gattone [46]	2001	Italy	MI	120	120	Case-control	MIF
Anderson [44]	1998	USA	CAD, MI	331	323	Case-control	MIF

CAD, coronary artery disease; IHD, ischemic heart disease; A, atherosclerosis; PAD, peripheral artery disease; SA, stable angina; SX, syndrome X; UA, unstable angina; MI, myocardial infarction.